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Results: Stage at RT: IIB 10 (5%), IIIA 69 (33%), IIIB+recurrent dis-
ease 128 (62%). Male/female ratio was 128 /79. The median and 2-year 
survival was 15.7 months and 34.3%. 45 cases of BM were observed. 
The median time to BM was 7.7 months. The actuarial risk of BM at 
2 years was 25.5%. In 69% of all BM (31 cases) it was the ﬁrst site of 
failure and in 10 cases BM remained the only site of failure. In logistic 
regression analyses female gender and adenocarcinoma were associated 
with higher risk of developing BM. The survival after diagnosis of BM 
was 2.8 months. The patient with BM being the ﬁrst site of recurrence 
had better prognosis than patients experiencing BM at a later stage (5.3 
vs. 2.0 months, p>0.0001). The prognosis after BM as ﬁrst failure were 
no worse than patients having other sites as ﬁrst distant failure (5.3 
vs. 4.9 months, p=0.7). If the patients, who died with BM as the only 
manifestation of recurrence, were censored at the time of death in the 
survival analysis, the median survival would increase by 1.4 months 
to 17.1 months, and the 2-year survival rate would increase by 1.7% to 
36.0%. 
In a Cox-multivariate analysis female gender, use of neoadjuvant che-
motherapy, and stage at RT was associated with poorer BM-RFS while 
adenocarcinoma was of borderline importance, and age and perfor-
mance status at RT were insigniﬁcant factors.
Conclusions: A signiﬁcant number of patients with locally advanced 
NSCLC, especially females and adenocarcinomas, experienced BM. 
The survival after diagnosis of BM as ﬁrst failure was no worse than 
patients experiencing other distant sites as ﬁrst failure, and the results 
indicate that PCI would add only little to survival
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Background: Many patients presenting with localized/locally ad-
vanced NSCLC are considered unsuitable for surgery; a signiﬁcant pro-
portion of these may be suitable for radical radiotherapy (radiotherapy 
given with curative intent). 
Clinical data suggest that: 
1. There is a dose-response effect with radiotherapy (RT) in NSCLC.
2. Shortening overall treatment time (acceleration) may limit tumour 
repopulation and improve outcomes.
Accelerated hypofractionated RT shortens overall treatment time by 
using fewer, larger fractions compared to conventional RT and the regi-
men most commonly used in the UK for NSCLC is the hypofraction-
ated schedule of 55Gy in 20 fractions over 4 weeks.
Dose escalation can be achieved by keeping fraction number the same 
and increasing the dose per fraction. This maintains the beneﬁts of 
acceleration, potentially maximizing the beneﬁt of any increase in total 
dose. 
There are three dose-limiting organs at risk (OARs) in radical RT for 
NSCLC and treatment is designed to keep the dose to these within pre-
deﬁned limits; for lungs, mean normalized tissue dose <17Gy (NTD-
mean), spinal cord <44Gy and oesophagus <58.5Gy. 
Conventionally, the dose prescribed for all patients in a particular 
department is the same as long as OAR limits are not exceeded. Doses 
received by OARs vary greatly between patients depending on the 
size and position of the tumour. Therefore, in some patients it should 
be possible to increase the dose prescribed whilst staying within OAR 
dose limits. In others, where OARs lie adjacent to the tumour within 
the high dose planning target volume (PTV), dose escalation will be 
limited.
Methods: We conducted a retrospective review of 10 consecutive radi-
cal RT plans in patients prescribed 50-55Gy in 20 fractions delivered 
using 3DCRT to assess the feasibility of a prospective isotoxic dose 
escalation study. Doses were increased until the ﬁrst OAR dose limit 
was reached. None of the treatment plans were changed.
Results: In 5/10 patients, lung NTDmean was the ﬁrst dose limit 
reached, and theoretical prescribed doses ranged from 77-166Gy in 20 
fractions. In 2/10 patients oesophagus was the dose limit ﬁrst reached 
(theoretical prescribed doses 62Gy and 129Gy). In 1/10 patients, the 
cord limited the theoretical prescribed dose to 81Gy. 2/10 patients had 
oesophagus in the PTV, and no escalation was possible. The dose to the 
heart was insigniﬁcant in all cases.
Conclusions: Individualised dose escalated isotoxic radical RT to pre-
deﬁned safe OAR limits may improve outcomes. We will shortly be 
assessing the feasibility of this concept a prospective study. 
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Introduction: Patients with NSCLC who are not suitable for surgery 
can present with locally advanced, non-metastatic disease that is too 
large for radical radiotherapy (RT). In this situation chemotherapy can 
be used to reduce tumour size such that disease can be encompassed 
within a radical RT volume. To our knowledge there is no evidence in 
the literature to support this practice. We have conducted a retrospec-
tive review of patients initially presenting with tumours deemed too 
large for curative treatment who received radical RT following a good 
response to chemotherapy. 
Methods: Patients were identiﬁed using ISCO, an in-house electronic 
database of all cancer patients referred to Velindre hospital. Data were 
collected retrospectively through ISCO and review of the case notes. 
Survival was assessed using the log-rank method.
Results: Between March 1998 and August 2005, 15 patients were iden-
tiﬁed. There were 11 men (73%, median age 69 years) and 4 women 
(27%, median age 63.5 years). In total, 40% of patients were stage 3, 
27% stage 2, 33% stage 1. All patients received between 1 and 4(me-
dian 3) cycles of platinum-based chemotherapy. The Mean maximum 
tumour diameter pre chemotherapy was 7.5cm, and post chemotherapy 
was 5cm. All patients were planned using 2D or 3D conformal RT, and 
post chemotherapy volumes were used for planning. Patients either 
received CHART or 55Gy in 20 fractions. In total 26% of patients had 
a complete response to RT, 26% a partial response and 26% stable 
disease. Response was not recorded in 22% of patients.
Median overall survival (OS) was 18 months (95% CI 15-21 months). 
In total 47% of patients have relapsed locally and 20% (3/15) of pa-
tients developed brain metastases. In 2 patients the brain was the only 
site of relapse.
